Newer Immunosuppressive Drugs: Their Potential Role in Rheumatoid Arthritis Therapy

Drosos, A.A.
March 2002
Drugs;2002, Vol. 62 Issue 6, p891
Academic Journal
Rheumatoid arthritis (RA) is a chronic immune-mediated disease characterised by chronic synovitis, which leads to cartilage damage and joint destruction. It is generally a progressive disease with radiographic evidence of joint damage, functional status decline and premature mortality. Proinflammatory cytokines, such as interleukin 1 and tumour necrosis factor α, play an important role in maintaining the chronicity of RA and mediating tissue damage. New approaches in the therapy of RA with anticytokine biological agents, which neutralise or block cytokines or their receptors, are now the first generation antirheumatic drugs in clinical practice. A better understanding of the signal transduction systems and gene regulation by transcription factors involved in cytokine production has opened the way for the discovery of novel therapeutic compounds useful in treating patients with RA. Overactivation of selective kinases or aberrant function of downstream transcription factors could help convert a normal immune response to a chronic disease state. This provides a unique opportunity for novel therapeutic interventions, since specific signal transduction or transcription factor targets might interrupt the perpetuation mechanisms in RA. The availability of potent and selective p38 mitogen activated protein kinase inhibitors provide a means in further dissecting the pathways implicated in cytokine production, which in turn maintain the chronicity of RA. Many studies conclude that these compounds are very useful in the treatment of chronic synovitis and therefore are very promising for RA treatment.


Related Articles

  • Immunosuppressive drugs in rheumatoid arthritis. Baum, John; Vaughan, John; Baum, J; Vaughan, J // Annals of Internal Medicine;Jul69, Vol. 71 Issue 1, p202 

    Editorial. Focuses on immunosuppressive therapy for the treatment of rheumatoid arthritis. Information on immunosuppressive agents; Efficacy of the agent; Mechanism of action and dosage; Side effects and contraindications.

  • Intermittent cyclophosphamide in refractory rheumatoid arthritis. Horslev-Petersen, Kim; Beyer, Jannie M.; Helin, Pekka // British Medical Journal (Clinical Research Edition);9/10/1983, Vol. 287 Issue 6394, p711 

    Examines the effectiveness of cyclophosphamide and methylprednisolone in treating patients with refractory rheumatoid arthritis. Importance of cyclophosphamide reduction on leucopenia development; Use of immunosuppressive agents in rheumatoid arthritis management; Relationship between bladder...

  • Risk for Zoster from the Vaccine in Immunosuppressed Persons.  // OB/GYN Clinical Alert;Sep2012 Clinical Briefs in Primary Care, p17 

    The article focuses on the restricted use of herpes zoster vaccine (ZOS) for the person who receives immunosuppressive treatments such as methotrexate for rheumatoid arthritis as ZOS is a live virus.

  • Tocilizumab cost effective in MTX-intolerant RA.  // PharmacoEconomics & Outcomes News;7/21/2012, Issue 658, p3 

    The article discusses research on the cost effectiveness of tocilizumab in patients with rheumatoid arthritis who are intolerant or have contraindications to methotrexate, referencing a study by C. Gibbons et al presented at the 13th Annual Congress of the European League Against Rheumatism.

  • Agency Says Biologic-Synthetic Mix Works Best For Arthritis. Young, Donna // BioWorld Today;11/26/2007, Vol. 18 Issue 228, p3 

    The article reports on a study by the Agency for Healthcare Research and Quality (AHRQ) which found that combining one synthetic drug with one of six biologic medications often works best to reduce joint swelling or tenderness in patients with rheumatoid arthritis (RA). AHRQ-funded researchers...

  • Sandimmun.  // Royal Society of Medicine: Medicines;2002, p487 

    The article presents information on the Sandimmun, a prescription-only preparation of the immunosupressant ciclosporin, which can be used to prevent tissue rejection in transplant patients and to treat severe, active rheumatoid arthritis and certain severe, resistant skin conditions.

  • SangCya.  // Royal Society of Medicine: Medicines;2002, p487 

    The article presents information on the SangCya, a prescription-only preparation of the immunosuppressant ciclosporin, which can be used to prevent tissue rejection in transplant patients and to treat severe, active rheumatoid arthritis and certain severe, resistant skin conditions.

  • First JAK inhibitor approved as second-line RA treatment. Sobieraj, Diana M. // Drug Topics;May2013, Vol. 157 Issue 5, p41 

    The article focuses on approval of tofacitinib drug for treatment of rheumatoid arthritis (RA) for adults who are intolerant to methotrexate. Tofacitinib is an oral nonbio-logic disease-modifying antirheumatic drug (DMARD) which is contraindicated for use with immunosuppressive agents like...

  • Methotrexate.  // Reactions Weekly;10/13/2007, Issue 1173, p17 

    The article describes the case of a 62-year-old man who developed aseptic meningitis while receiving intramuscular methotrexate for rheumatoid arthritis. He was hospitalised due to headache, neck pain and rigidity, fever, chills, abdominal pain and tenosynovitis. Methotrexate and etanercept were...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics